Summary
Global Markets Direct’s, ‘AIMM Therapeutics B.V. - Product Pipeline Review - 2016’, provides an overview of the AIMM Therapeutics B.V.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by AIMM Therapeutics B.V., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of AIMM Therapeutics B.V.
- The report provides overview of AIMM Therapeutics B.V. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AIMM Therapeutics B.V.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AIMM Therapeutics B.V.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate AIMM Therapeutics B.V.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AIMM Therapeutics B.V.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AIMM Therapeutics B.V.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
AIMM Therapeutics B.V. Snapshot 6
AIMM Therapeutics B.V. Overview 6
Key Information 6
Key Facts 6
AIMM Therapeutics B.V. - Research and Development Overview 7
Key Therapeutic Areas 7
AIMM Therapeutics B.V. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
AIMM Therapeutics B.V. - Pipeline Products Glance 14
AIMM Therapeutics B.V. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
AIMM Therapeutics B.V. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
AIMM Therapeutics B.V. - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
AIMM Therapeutics B.V. - Drug Profiles 18
CR-8020 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody for Acute Myelocytic Leukemia 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody for Colon Carcinoma 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody for Cytomegalovirus Infections 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody for Hepatitis C Infection 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for Human Rhinovirus Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for Melanoma 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody for MRSA Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody for Multiple Myeloma 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody for Pancreatic Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AM-18 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AM-28 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for Clostridium Difficile Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibodies for Hepatitis B Infection 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AIMM Therapeutics B.V. - Pipeline Analysis 35
AIMM Therapeutics B.V. - Pipeline Products by Target 35
AIMM Therapeutics B.V. - Pipeline Products by Route of Administration 36
AIMM Therapeutics B.V. - Pipeline Products by Molecule Type 37
AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action 38
AIMM Therapeutics B.V. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41
List of Tables
AIMM Therapeutics B.V., Key Information 6
AIMM Therapeutics B.V., Key Facts 6
AIMM Therapeutics B.V. - Pipeline by Indication, 2016 8
AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016 10
AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016 11
AIMM Therapeutics B.V. - Out-Licensed Products in Pipeline, 2016 12
AIMM Therapeutics B.V. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
AIMM Therapeutics B.V. - Phase II, 2016 14
AIMM Therapeutics B.V. - Preclinical, 2016 15
AIMM Therapeutics B.V. - Discovery, 2016 16
AIMM Therapeutics B.V. - Unknown, 2016 17
AIMM Therapeutics B.V. - Pipeline by Target, 2016 35
AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016 36
AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016 37
AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016 38
List of Figures
AIMM Therapeutics B.V. - Pipeline by Top 10 Indication, 2016 8
AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016 10
AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016 11
AIMM Therapeutics B.V. - Pipeline by Target, 2016 35
AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016 36
AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016 37
AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016 38
